Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Alendronic acid
Drug ID BADD_D00066
Description Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label][A959].
Indications and Usage Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone[FDA Label][A959,A176750]. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min[FDA Label].
Marketing Status approved
ATC Code M05BA04
DrugBank ID DB00630
KEGG ID D07119
MeSH ID D019386
PubChem ID 2088
TTD Drug ID D09KLR
NDC Product Code Not Available
UNII X1J18R4W8P
Synonyms Alendronate | 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate | Aminohydroxybutane Bisphosphonate | MK-217 | MK 217 | MK217 | Alendronate Monosodium Salt, Trihydrate | Alendronate Sodium | Fosamax
Chemical Information
Molecular Formula C4H13NO7P2
CAS Registry Number 66376-36-1
SMILES C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Carotid artery disease17.08.02.016; 24.03.05.0090.000154%-
Spider vein23.06.03.006; 24.10.04.0030.000044%-
Low turnover osteopathy14.04.04.015; 15.02.03.016; 20.01.01.0100.016541%-
Spondylolisthesis12.04.04.008; 15.10.04.0040.000947%-
Periodic limb movement disorder15.05.03.034; 17.15.04.006; 19.02.05.0090.000044%-
Asthmatic crisis22.03.01.0180.000044%-
Oroantral fistula07.11.05.015; 22.04.06.0050.000044%-
Medial tibial stress syndrome15.02.04.0360.000044%-
Oral cavity fistula07.11.05.0140.000352%
Stress urinary incontinence20.02.02.0220.000572%-
Weight bearing difficulty15.03.05.034---
Retroperitoneal lymphadenopathy01.09.01.029; 07.07.01.0120.000044%-
Carotid arteriosclerosis17.08.02.015; 24.04.06.0310.000066%-
Fistula discharge08.01.03.069; 15.03.02.0150.000286%-
Right atrial dilatation02.04.02.0320.000044%-
Left atrial dilatation02.04.02.0250.000154%-
Heart valve incompetence02.07.02.0030.000066%-
Reflux laryngitis22.04.01.0070.000066%-
Vertebral foraminal stenosis15.01.08.015; 17.10.01.0240.000418%-
Limb asymmetry15.10.03.0090.000903%
Cerebral small vessel ischaemic disease17.08.02.020; 24.04.06.0340.000088%-
Bone deformity15.10.03.0060.000066%-
Exposed bone in jaw15.02.04.0340.000594%-
Soft tissue mass15.03.02.0190.000088%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.000088%-
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000176%-
Large intestine benign neoplasm07.20.01.013; 16.05.01.0040.000066%-
Idiopathic orbital inflammation06.04.11.0020.000066%-
Chronic papillomatous dermatitis12.02.16.002; 23.01.04.0050.000066%-
Lumbosacral radiculopathy17.10.03.0050.000352%-
The 36th Page    First    Pre   36 37 38 39    Next   Last    Total 39 Pages